Several Phase 3 trials are under way. The ACHIEVE trial (NCT06096844) is testing chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → combined with immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → versus immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → alone for older adults with advanced lung cancer. A Phase 3 study (NCT06732401) is adding ceralasertib, an ATR (ataxia telangiectasia and Rad3-related) kinase inhibitor, to immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for NSCLC. The INSIGHT trial (NCT06498635) is evaluating durvalumab after surgery for early-stage NSCLC in people with no residual cancer cells after standard treatment. A Phase 3 study (NCT07431827) is testing pembrolizumab with and without a KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C inhibitor in resected KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C-mutated NSCLC. Sacituzumab tirumotecan, an antibody-drug conjugate, is being compared to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in a Phase 3 trial (NCT06305754) for EGFR-mutated NSCLC that has progressed on prior EGFR inhibitors.
For SCLC, a Phase 2 study (NCT07155174) is evaluating ABBV-706 combined with atezolizumab as a first-line option in extensive-stage disease. A Phase 3 trial (NCT07055581) is testing durvalumab consolidation after chemoradiotherapy for limited-stage SCLC. Preclinical research is investigating strategies to overcome EGFR inhibitor resistance, including HIF-1 alpha (hypoxia-inducible factor 1 alpha) targeting. Real-world data from Australia show KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → in up to 30 percent of lung adenocarcinomas, highlighting the expanding relevance of routine molecular testing.
Where the evidence stands
The most mature evidence in NSCLC supports EGFR inhibitors, ALK inhibitors such as lorlatinib, and immune checkpoint inhibitors, all backed by Phase 3 data. KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C inhibitors entered clinical practice on Phase 2 data and are now established, with Phase 3 studies exploring broader indications. BRAF-targeted combinations have Phase 3 support. For SCLC, immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →-chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → combinations have Phase 3 evidence for extensive-stage disease; limited-stage SCLC is being studied in ongoing Phase 3 trials. Adjuvant and perioperative immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → approaches for NSCLC are at the Phase 3 stage. Novel antibody-drug conjugates and targeted combinations for resistance settings are mostly at Phase 1 to Phase 2. Screening research is also exploring how to extend the benefits of early detection to underserved communities.
What this means for people affected
Lung cancer treatment has evolved considerably, with a growing number of targeted options for people whose tumors carry specific molecular alterations. Testing for EGFR, ALK, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →, and BRAF mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → has become a standard step in guiding treatment decisions for NSCLC, particularly adenocarcinoma. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → has extended survival for many people with advanced NSCLC, though response varies significantly. Small cell lung cancer remains difficult to treat, and research is actively seeking to improve on currently available options. For those with early-stage disease, ongoing trials are exploring whether adding immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → after surgery can reduce recurrence. Persistent disparities in lung cancer screening rates among Black adults and other underserved groups remain an important concern.
Last updated April 4, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
New Technique Simplifies Lung Cancer Surgery
Researchers developed a new method for performing a type of lung cancer surgery called robotic right upper lobectomy. They compared this new technique to the traditional method in a small group of patients. The new technique seemed to reduce the time it took to perform the surgery.
Why it matters: This finding could make lung cancer surgery easier and faster for surgeons in challenging cases.
Small sample size, with 7 patients in the new technique group and 37 in the control group.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Rare skin symptoms may signal lung cancer
Researchers reported a case of a man who developed skin swellings that were initially misdiagnosed as an infection. Later, he was diagnosed with small-cell lung cancer that had spread to his skin, lungs, and other organs. Unfortunately, his condition worsened rapidly despite treatment.
Why it matters: This case highlights the importance of considering rare skin symptoms in the context of lung cancer diagnosis.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
New Strategy to Improve Lung Cancer Treatment
Researchers studied how a protein called HIF-1α affects lung cancer treatment. They found that targeting this protein can make a common lung cancer drug more effective. This approach may help overcome a common problem with lung cancer treatment.
Why it matters: This finding could lead to new ways to improve lung cancer treatment and help patients with this disease.
Efficacy
Combined treatment with HIF-1α siRNA and erlotinib synergistically suppressed cell proliferation, induced apoptosis, and inhibited invasion more effectively than single-agent treatments.
This study was conducted in lab experiments using cell lines.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
New Blood Test for Lung Cancer Shows Promise
Researchers used a special blood test to look for differences in proteins between people with lung cancer and those with harmless lung nodules. They found some differences, but more research is needed to confirm these findings. This early study suggests that blood tests might be useful for detecting lung cancer earlier.
Why it matters: This finding could lead to better ways to diagnose and manage lung cancer, especially in people who are at high risk.
The study was small and needs to be repeated with a larger group of people.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
New Method for Accurate Lung Cancer Diagnosis
Researchers developed a new way to diagnose lung cancer without using special stains. They used a computer algorithm to analyze images of lung tissue and found that it could accurately identify different types of lung cancer. This method may help doctors make faster and more accurate diagnoses.
Why it matters: This finding could help doctors make more accurate diagnoses and improve treatment options for lung cancer patients.
Efficacy
The results demonstrate the exceptional ability of this approach for NSCLC subtype differentiation, achieving an area under the curve above 0.981 and 0.996 for binary- and multi-class classification.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Respiratory diseases linked to higher lung cancer risk
Researchers analyzed data from over 400,000 people in the UK to see if respiratory diseases are associated with lung cancer. They found that people with respiratory diseases were more likely to develop lung cancer, especially those with acute respiratory infections. The study suggests a possible link, but more research is needed to confirm it.
Why it matters: This finding could help researchers better understand lung cancer risk and develop new ways to identify people at higher risk.
The study followed participants for a mean of 10.44 years, and 2189 cases of lung cancer were identified.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: April 3, 2026
Mindfulness Helps Lung Cancer Patients Manage Fatigue and Emotions
Researchers studied whether mindfulness-based stress reduction can help lung cancer patients feel less tired, anxious, and depressed. They found that patients who practiced mindfulness for 8 weeks reported improvements in these areas. However, it's unclear how long these benefits last.
Why it matters: This finding could lead to new ways to support lung cancer patients during and after treatment.
Efficacy
Fatigue levels in the MBSR group peaked at the fourth week but returned close to baseline levels by 3 months post-intervention, while the Control group maintained elevated fatigue scores (P < .05).
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
Genetic link to lung cancer risk found in new study
Researchers used a genetic approach to investigate the link between a protein called hepatocyte growth factor and lung cancer. They found that people with higher levels of this protein were more likely to develop lung cancer, especially a type called lung adenocarcinoma. However, more research is needed to confirm these findings.
Why it matters: This study provides new insights into the potential causes of lung cancer, which could help scientists develop more effective prevention and treatment strategies.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Barriers to Lung Cancer Screening in Black Adults in NYC
Researchers interviewed Black adults in New York City to understand why they don't get lung cancer screenings. They found that lack of knowledge, mistrust of healthcare, and limited access to screening services are major barriers. More research is needed to develop effective solutions.
Why it matters: This study highlights the need for culturally tailored interventions to promote lung cancer screening among Black adults.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
Gene Linked to Lung Cancer Progression
Researchers used a statistical method called Mendelian randomization to identify a gene called STMN1 that may contribute to lung cancer progression. They found that high levels of STMN1 were associated with a shorter survival and a less effective immune response in lung cancer patients. The study suggests that STMN1 may play a role in the development of lung cancer, but more research is needed to confirm this.
Why it matters: This finding could lead to new targets for lung cancer therapy and a better understanding of how the disease progresses.
The study was conducted in a lab setting and more research is needed to confirm the findings in humans.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Gut Bacteria Linked to Lung Cancer Prognosis
Researchers analyzed the gut bacteria of lung cancer patients to see if it could predict their prognosis after surgery. They found that patients with certain types of gut bacteria had better survival rates. The study suggests that targeting these bacteria might help improve treatment outcomes.
Why it matters: This finding could help doctors identify patients who are at higher risk of recurrence and develop new treatments to improve their outcomes.
Efficacy
Patients with a high PNI showed a 5-y survival hazard ratio of 0.3889.
The study included a mix of retrospective and prospective patients, and the results were based on a specific cutoff value for a prognostic nutritional index.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 2, 2026
Rare Blood Disorder in Lung Cancer Patient Treated with Nivolumab
Researchers reported a rare case of a blood disorder called febrile neutropenia in a patient with lung cancer who was being treated with the medication nivolumab. The patient's bone marrow showed signs of an immune-mediated reaction, which was treated with antibiotics and a growth factor. The case highlights the importance of monitoring for this side effect.
Why it matters: This finding matters because it shows that rare but serious side effects can occur even late in treatment with immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →.
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →MutationsA change in DNA sequence that can drive cancer development.Click for full explanation →
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →
MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12Cm NSCLC (MK-1084-013)
Testing the Addition of AZD6738 (Ceralasertib) to ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Testing the Addition of the Pill ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for Non-small Cell Lung Cancer
